Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-12-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled as an "Information Disclosure Management System" for a company, detailing the principles, procedures, responsibilities, and legal framework for information disclosure. It extensively covers regulatory compliance, insider information management, reporting obligations, and internal controls related to disclosure. There is no actual financial data, financial statements, earnings results, or audit opinions presented. Instead, it is a governance and procedural document outlining how the company manages and discloses information to the public and regulators. This fits the description of Governance Information (CGR), which includes reports detailing the company's internal rules, board structure, and governance practices. The document length is substantial and it is not a mere announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CGR with high confidence.
2022-12-30 Chinese
董事会秘书工作细则
Governance Information Classification · 100% confidence The document is titled '董事会秘书工作细则' which translates to 'Board Secretary Work Rules' or 'Board Secretary Procedures'. It outlines the duties, qualifications, appointment, and legal responsibilities of the company's board secretary. The content focuses on governance, compliance with laws and regulations, and internal company procedures related to the board secretary role. There are no financial statements, earnings data, or investor presentations. It is not an announcement of a report but a governance-related internal rules document. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-12-30 Chinese
关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the use of part of the over-raised funds to permanently supplement working capital. It details the approval by the board of directors, supervisory board, independent directors, and the sponsor institution's verification. The document references regulatory compliance with the Shenzhen Stock Exchange and China Securities Regulatory Commission rules. It is a formal announcement about the company's capital usage plan and upcoming shareholder meeting approval. The document length is 3283 characters, which is relatively short and focused on a specific capital usage update rather than a full financial report or audit. There are no financial statements or comprehensive financial data presented. This fits the category of a Capital/Financing Update (CAP) as it concerns the use of raised funds and capital structure changes, not a full annual or interim report, audit report, or other categories.
2022-12-30 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Work Rules" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the structure, responsibilities, and procedures of the remuneration and assessment committee of the board. The content focuses on governance practices related to board and senior management compensation and performance evaluation. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, and no mention of any report publication or regulatory filing. The document is a governance-related internal rules document about board remuneration and assessment committee operations. Therefore, it fits best under Governance Information (CGR). The document length is 2393 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, the classification is CGR with high confidence.
2022-12-30 Chinese
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee meetings, independent director opinions, and the approval process for using up to 400 million RMB of idle raised funds for cash management purposes. The document includes information about the raised funds, their intended use, risk control measures, and compliance with regulatory requirements. It is a formal announcement about a financing-related activity (use of raised funds for cash management) rather than a full financial report or audit. The document length is under 5,000 characters and it is an announcement of a financing activity, not a report or detailed financial statement. Therefore, it fits best under Capital/Financing Update (CAP).
2022-12-30 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2022年度持续督导培训情况的报告
Regulatory Filings Classification · 90% confidence The document is a report from a sponsoring institution (中信证券股份有限公司) about a 2022 annual continuous supervision training conducted for a listed company (上海泓博智源医药股份有限公司). It details the training time, participants, content, and cooperation from the company. The document is short (598 characters) and focuses on a specific training event related to regulatory compliance and supervision, not on financial results, audit, or management changes. It is not an announcement of a report publication but a standalone report on the training activity. This type of document does not fit into financial reports, earnings, or governance changes but is related to regulatory compliance and supervisory activities. Given the options, the closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-12-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.